Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1995 Mar;71(833):136–142. doi: 10.1136/pgmj.71.833.136

Prostate disease: management options for the primary healthcare team. Report of a working party of the British Prostate Group.

G D Chisholm 1, S J Carne 1, J M Fitzpatrick 1, N J George 1, J C Gingell 1, J W Keen 1, R S Kirby 1, D Kirk 1, E P O'Donoghue 1, W B Peeling 1, et al.
PMCID: PMC2398180  PMID: 7538216

Abstract

The prostate gland has attracted a remarkable increase in interest in the past few years. The two most common diseases of this gland, benign prostatic hyperplasia and carcinoma of the prostate, have been brought into greater prominence by new diagnostic methods, public interest, and a wider choice of surgical and non-surgical treatments. Uncertainty about the significance of these changes has occurred because of the rapidity of change, the profusion of statements, opinions and promotions, and the relatively little guidance available from the profession. Ten urologists and two general practitioners have reviewed the relevant evidence about these two prostate diseases and the newer diagnostic methods; their conclusions are summarised here. Management options and guidance on clinical practice are also discussed. Because of a number of unresolved diagnostic and management issues, detailed requirements for practice guidelines have not been specified.

Full text

PDF
136

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball A. J., Feneley R. C., Abrams P. H. The natural history of untreated "prostatism". Br J Urol. 1981 Dec;53(6):613–616. doi: 10.1111/j.1464-410x.1981.tb03273.x. [DOI] [PubMed] [Google Scholar]
  2. Barry M. J., Fowler F. J., Jr, O'Leary M. P., Bruskewitz R. C., Holtgrewe H. L., Mebust W. K. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. J Urol. 1992 Nov;148(5):1558–1564. doi: 10.1016/s0022-5347(17)36967-7. [DOI] [PubMed] [Google Scholar]
  3. Benson M. C., Whang I. S., Olsson C. A., McMahon D. J., Cooner W. H. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992 Mar;147(3 Pt 2):817–821. doi: 10.1016/s0022-5347(17)37394-9. [DOI] [PubMed] [Google Scholar]
  4. Brawer M. K., Chetner M. P., Beatie J., Buchner D. M., Vessella R. L., Lange P. H. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992 Mar;147(3 Pt 2):841–845. doi: 10.1016/s0022-5347(17)37401-3. [DOI] [PubMed] [Google Scholar]
  5. Carter H. B., Pearson J. D., Metter E. J., Brant L. J., Chan D. W., Andres R., Fozard J. L., Walsh P. C. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992 Apr 22;267(16):2215–2220. [PMC free article] [PubMed] [Google Scholar]
  6. Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. doi: 10.1056/NEJM199104253241702. [DOI] [PubMed] [Google Scholar]
  7. Chadwick D. J., Kemple T., Astley J. P., MacIver A. G., Gillatt D. A., Abrams P., Gingell J. C. Pilot study of screening for prostate cancer in general practice. Lancet. 1991 Sep 7;338(8767):613–616. doi: 10.1016/0140-6736(91)90615-v. [DOI] [PubMed] [Google Scholar]
  8. Chodak G. W. Screening for prostate cancer in 1993: is it appropriate, or not? Semin Urol. 1993 May;11(2):47–49. [PubMed] [Google Scholar]
  9. Cooner W. H., Mosley B. R., Rutherford C. L., Jr, Beard J. H., Pond H. S., Terry W. J., Igel T. C., Kidd D. D. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990 Jun;143(6):1146–1154. doi: 10.1016/s0022-5347(17)40211-4. [DOI] [PubMed] [Google Scholar]
  10. Costello A. J., Bowsher W. G., Bolton D. M., Braslis K. G., Burt J. Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol. 1992 Jun;69(6):603–608. doi: 10.1111/j.1464-410x.1992.tb15631.x. [DOI] [PubMed] [Google Scholar]
  11. Evans J. W., Singer M., Chapple C. R., Macartney N., Walker J. M., Milroy E. J. Haemodynamic evidence for cardiac stress during transurethral prostatectomy. BMJ. 1992 Mar 14;304(6828):666–671. doi: 10.1136/bmj.304.6828.666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. FRANKS L. M. Latent carcinoma of the prostate. J Pathol Bacteriol. 1954 Oct;68(2):603–616. doi: 10.1002/path.1700680233. [DOI] [PubMed] [Google Scholar]
  13. Fowler F. J., Jr, Wennberg J. E., Timothy R. P., Barry M. J., Mulley A. G., Jr, Hanley D. Symptom status and quality of life following prostatectomy. JAMA. 1988 May 27;259(20):3018–3022. [PubMed] [Google Scholar]
  14. Garraway W. M., Collins G. N., Lee R. J. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991 Aug 24;338(8765):469–471. doi: 10.1016/0140-6736(91)90543-x. [DOI] [PubMed] [Google Scholar]
  15. Glynn R. J., Campion E. W., Bouchard G. R., Silbert J. E. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 1985 Jan;121(1):78–90. [PubMed] [Google Scholar]
  16. Gormley G. J., Stoner E., Bruskewitz R. C., Imperato-McGinley J., Walsh P. C., McConnell J. D., Andriole G. L., Geller J., Bracken B. R., Tenover J. S. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992 Oct 22;327(17):1185–1191. doi: 10.1056/NEJM199210223271701. [DOI] [PubMed] [Google Scholar]
  17. Hennigan T. W., Franks P. J., Hocken D. B., Allen-Mersh T. G. Rectal examination in general practice. BMJ. 1990 Sep 8;301(6750):478–480. doi: 10.1136/bmj.301.6750.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Heyns C. F., Rittoo D., Sutherland G. R., Davie I. T., Scott N. B., Chisholm G. D. Intra-operative myocardial ischaemia detected by biplane transoesophageal echocardiography during transurethral prostatectomy. Br J Urol. 1993 Jun;71(6):716–720. doi: 10.1111/j.1464-410x.1993.tb16072.x. [DOI] [PubMed] [Google Scholar]
  19. Isaacs J. T. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl. 1990;3:1–7. doi: 10.1002/pros.2990170502. [DOI] [PubMed] [Google Scholar]
  20. Jones D. R., Roberts E. E., Griffiths G. J., Parkinson M. C., Evans K. T., Peeling W. B. Assessment of volume measurement of the prostate using per-rectal ultrasonography. Br J Urol. 1989 Nov;64(5):493–495. doi: 10.1111/j.1464-410x.1989.tb05284.x. [DOI] [PubMed] [Google Scholar]
  21. Lepor H., Auerbach S., Puras-Baez A., Narayan P., Soloway M., Lowe F., Moon T., Leifer G., Madsen P. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992 Nov;148(5):1467–1474. doi: 10.1016/s0022-5347(17)36941-0. [DOI] [PubMed] [Google Scholar]
  22. Malone P. R., Cook A., Edmonson R., Gill M. W., Shearer R. J. Prostatectomy: patients' perception and long-term follow-up. Br J Urol. 1988 Mar;61(3):234–238. doi: 10.1111/j.1464-410x.1988.tb06386.x. [DOI] [PubMed] [Google Scholar]
  23. Mettlin C., Lee F., Drago J., Murphy G. P. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer. 1991 Jun 15;67(12):2949–2958. doi: 10.1002/1097-0142(19910615)67:12<2949::aid-cncr2820671202>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  24. Muir C. S., Nectoux J., Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol. 1991;30(2):133–140. doi: 10.3109/02841869109092336. [DOI] [PubMed] [Google Scholar]
  25. Oesterling J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991 May;145(5):907–923. doi: 10.1016/s0022-5347(17)38491-4. [DOI] [PubMed] [Google Scholar]
  26. Pantelides M. L., Bowman S. P., George N. J. Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Br J Urol. 1992 Sep;70(3):299–303. doi: 10.1111/j.1464-410x.1992.tb15735.x. [DOI] [PubMed] [Google Scholar]
  27. Roos N. P., Ramsey E. W. A population-based study of prostatectomy: outcomes associated with differing surgical approaches. J Urol. 1987 Jun;137(6):1184–1188. doi: 10.1016/s0022-5347(17)44442-9. [DOI] [PubMed] [Google Scholar]
  28. Roos N. P., Wennberg J. E., Malenka D. J., Fisher E. S., McPherson K., Andersen T. F., Cohen M. M., Ramsey E. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med. 1989 Apr 27;320(17):1120–1124. doi: 10.1056/NEJM198904273201705. [DOI] [PubMed] [Google Scholar]
  29. Schröder F. H. Prostate cancer: to screen or not to screen? BMJ. 1993 Feb 13;306(6875):407–408. doi: 10.1136/bmj.306.6875.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Stamey T. A., Dietrick D. D., Issa M. M. Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J Urol. 1993 Mar;149(3):510–515. doi: 10.1016/s0022-5347(17)36131-1. [DOI] [PubMed] [Google Scholar]
  31. Wang M. C., Valenzuela L. A., Murphy G. P., Chu T. M. Purification of a human prostate specific antigen. Invest Urol. 1979 Sep;17(2):159–163. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES